Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
18.70
-0.37 (-1.94%)
Nov 12, 2026, 4:00 PM EST - Market closed
Immunome Revenue
In the year 2025, Immunome had annual revenue of $6.94M, down -23.23%. That makes Immunome the 40,665th largest company in the world by revenue and 5,422nd in the United States.
Revenue (ttm)
$6.94M
Revenue Growth
-23.23%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
267
Market Cap
2.21B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.94M | -2.10M | -23.23% |
| Dec 31, 2024 | 9.04M | -4.98M | -35.50% |
| Dec 31, 2023 | 14.02M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.13B |
| Aurinia Pharmaceuticals | 321.74M |
| Vir Biotechnology | 302.80M |
| Septerna | 96.27M |
| Recursion Pharmaceuticals | 68.23M |
| Celldex Therapeutics | 158.00K |
IMNM News
- 2 days ago - Immunome registers to sell 4.43M shares of common stock for holders - TheFly
- 2 days ago - Immunome files automatic mixed securities shelf - TheFly
- 2 days ago - Immunome price target lowered to $30 from $33 at Piper Sandler - TheFly
- 2 days ago - Immunome price target lowered to $23 from $24 at Stifel - TheFly
- 2 days ago - Immunome Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 3 days ago - Immunome reports Q3 EPS (76c), consensus (60c) - TheFly
- 3 days ago - Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 3 days ago - Immunome Earnings release: Q3 2026 - Filings